Sintilimab: all 353 studies that test it

Page 1 of 4. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingNCT07893340Phase 2
• Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingNCT07879599Phase 2/3
• Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingNCT07879586Phase 2/3
• A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingNCT07878221Phase 2
• Sintilimab Combined With Chemoradiotherapy as Neoadjuvant Therapy for Locally Advanced Gastroesophageal Junction CancerNot yet recruitingNCT07859410Not applicable
• A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)RecruitingNCT07852091Phase 2
• Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell CarcinomaNot yet recruitingNCT07827872Phase 3
• A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerNot yet recruitingNCT07819019Phase 2
• Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis BNot yet recruitingNCT07809165Not applicable
• Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract CancerRecruitingNCT07797816Phase 2
• A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
• GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07768943Phase 2
• Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Phase 1/2
• Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Phase 2
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCRecruitingNCT07748325Phase 2
• Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic CancerNot yet recruitingNCT07745790Phase 2
• A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaNot yet recruitingNCT07740993Phase 2
• To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMRNot yet recruitingNCT07738042Not applicable
• Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 TrialRecruitingNCT07722754Phase 2
• Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2
• Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Not yet recruitingNCT07714317Phase 1/2
• Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell CarcinomaRecruitingNCT07692152Phase 3
• Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term ProgressionRecruitingNCT07670026Phase 2
• Sintilimab Plus Gossypol Acetate in Advanced Colorectal CancerNot yet recruitingNCT07656766Phase 2
• Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07643623Phase 2/3
• Ipilimumab (N01) Plus Sintilimab and Modified XELOX as Conversion Therapy in Unresectable Locally Advanced Gastric CancerNot yet recruitingNCT07638631Phase 2
• Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical TrialRecruitingNCT07594925Phase 2
• The DoHAICs Study Expansion PhaseNot yet recruitingNCT07584018Phase 2
• Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDSNot yet recruitingNCT07579247Phase 1/2
• A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07574528Phase 2
• Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaRecruitingNCT07560488Phase 2
• A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular CarcinomaRecruitingNCT07557251Phase 1
• Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 2
• Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07515625Phase 2
• Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal CanceNot yet recruitingNCT07509424Phase 2
• A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerRecruitingNCT07506109Phase 2
• A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT07492615Phase 2
• TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskNot yet recruitingNCT07487662Phase 2
• IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07483567Phase 2
• SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARCRecruitingNCT07474103Not applicable
• Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCRecruitingNCT07459296Phase 3
• GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm StudyRecruitingNCT07457281Phase 1
• Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaRecruitingNCT07416890Phase 2
• Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung CancerRecruitingNCT07410975Phase 2
• Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After SurgeryRecruitingNCT07400302Phase 2
• Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal CancerRecruitingNCT07398326Phase 2
• Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell CarcinomaRecruitingNCT07371611Phase 3
• Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable HepatocellularNot yet recruitingNCT07352007Phase 2
• A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSLRecruitingNCT07350850Phase 2
• Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular ClassificationRecruitingNCT07319429Phase 2/3
• Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLCRecruitingNCT07309952Phase 2
• A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric CancerRecruitingNCT07263386Phase 2
• Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric CancerRecruitingNCT07194005Phase 2
• Adjuvant Radiotherapy of Sintilimab Versus TACE for HCCRecruitingNCT07186621Phase 3
• Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07156019Phase 2
• Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)RecruitingNCT07120698Phase 2
• Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical CancerNot yet recruitingNCT07088731Phase 2
• Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT07079410Phase 2
• Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver ResectionNot yet recruitingNCT07077798Not applicable
• Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerRecruitingNCT07061535Phase 2
• A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System TumorsNot yet recruitingNCT07053150Phase 2
• A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCNot yet recruitingNCT07038460Phase 2
• IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric CancerRecruitingNCT07025889Phase 1/2
• Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric CancerNot yet recruitingNCT07018063Phase 2
• Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4
• Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）Not yet recruitingNCT07007767Phase 2
• A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal CancerRecruitingNCT06979908Phase 2
• Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic CholangiocarcinomaRecruitingNCT06956716Phase 1/2
• Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon CancerEnrolling by invitationNCT06931808Phase 4
• Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCCRecruitingNCT06904014Phase 2
• Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.Not yet recruitingNCT06888648Phase 1/2
• Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal CancerRecruitingNCT06841159Phase 2
• HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of RecurrenceRecruitingNCT06812039Phase 2
• Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal CancerRecruitingNCT06776757Phase 1/2
• BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingNCT06761911Phase 4
• Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJRecruitingNCT06761846Phase 2
• Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06718205Phase 2
• A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)RecruitingNCT06709417Phase 2
• Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal CancerRecruitingNCT06698757Phase 2
• Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric CancerNot yet recruitingNCT06697366Phase 2
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLCNot yet recruitingNCT06688656Phase 2
• Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal CancerRecruitingNCT06685276Phase 2
• Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal CarcinomaNot yet recruitingNCT06680115Phase 2
• Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTTRecruitingNCT06664996Phase 2
• CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRCNot yet recruitingNCT06652412Phase 2
• Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingNCT06620822Phase 2
• Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerRecruitingNCT06584032Phase 3
• Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell LymphomaRecruitingNCT06583083Phase 2
• A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver MetastasisNot yet recruitingNCT06564298Phase 2
• Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaRecruitingNCT06558227Phase 2
• A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric CancerRecruitingNCT06555471Phase 2
• ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal CancerRecruitingNCT06543836Phase 2
• Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeMRecruitingNCT06543069Phase 2
• Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination TherapyNot yet recruitingNCT06523049Phase 2
• Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular CarcinomaNot yet recruitingNCT06512467Phase 2
• A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung CancerRecruitingNCT06512207Not applicable
• A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsRecruitingNCT06497985Phase 3
• Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCCRecruitingNCT06494943Phase 1/2

← Sintilimab overview